Stocks and Investing Stocks and Investing
Wed, August 7, 2024

Charles Duncan Maintained (ACAD) at Buy with Decreased Target to $28 on, Aug 7th, 2024


Published on 2024-10-28 13:19:28 - WOPRAI, Charles Duncan
  Print publication without navigation


Charles Duncan of Cantor Fitzgerald, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Buy with Decreased Target from $37 to $28 on, Aug 7th, 2024.

Charles has made no other calls on ACAD in the last 4 months.



There are 9 other peers that have a rating on ACAD. Out of the 9 peers that are also analyzing ACAD, 4 agree with Charles's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Tazeen Ahmad of "B of A Securities" Maintained at Hold with Decreased Target to $22 on, Friday, May 10th, 2024
  • Uy Ear of "Mizuho" Maintained at Hold with Decreased Target to $21 on, Thursday, May 9th, 2024
  • Paul Matteis of "Stifel" Maintained at Hold with Decreased Target to $21 on, Thursday, May 9th, 2024
  • Jay Olson of "Oppenheimer" Maintained at Hold and Held Target at $19 on, Monday, May 6th, 2024


These are the ratings of the 5 analyists that currently disagree with Charles


  • Keith Tapper of "BMO Capital" Initiated at Buy and Held Target at $31 on, Thursday, June 27th, 2024
  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $27 on, Thursday, May 9th, 2024
  • David Hoang of "Citigroup" Maintained at Strong Buy and Held Target at $30 on, Thursday, May 9th, 2024
  • Joel Beatty of "Baird" Maintained at Buy with Decreased Target to $28 on, Thursday, May 9th, 2024
  • Ashwani Verma of "UBS" Maintained at Strong Buy with Decreased Target to $27 on, Tuesday, April 30th, 2024
Contributing Sources